Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
Recruiting now · Phase 1
Conditions studied: Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma
In brief
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphodepleting chemotherapy in patients ≤ 21 years of age with relapsed/refractory B7-H3+ sarcomas. Secondary objectives: * To describe the antitumor activity of B7-H3-CAR T cells in combination with HFRT * To determine if B7-H3-CAR T cells traffic to tumor sites after combination treatment with HFRT
Key facts
- Study ID
- NCT07222735
- Run by
- St. Jude Children's Research Hospital
- People needed
- 42
- Starts
- 2026-01-21
- Expected to finish
- 2031-11-05
- Last updated by the study team
- 2026-02-09
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- a previously collected, autologous leukapheresis product can be used for T cell production
- Collection and manufacturing eligibility
- Age ≤ 21 years old
- B7-H3+ sarcoma; B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) using any previously obtained biopsy; a tumor is considered B7-H3 positive with a H score greater than or equal to 100
- Osteosarcoma
- Ewing Sarcoma
- Rhabdomyosarcoma Non-rhabdomyosarcoma soft tissue sarcomas
- Evidence of relapsed (cancer that has completely responded [i.e., no evidence of disease using standard imaging modalities] to first-line therapy but has recurred for the first or subsequent time); or refractory (cancer that does not respond completely to treatment; cancer may be resistant at the beginning or may become resistant during treatment) disease after standard first-line therapy
- Evaluable disease with presence of at least one lesion amenable to hypofractionated radiation therapy
- For dose expansion cohort: participants must also have additional evaluable disease beyond planned radiation field
- Estimated life expectancy of > 12 weeks
- Karnofsky or Lansky (age-dependent) performance score ≥ 60
- Participants with mobility limitations due to prior surgical intervention (i.e., amputation) but who are up in wheelchair or with other assistive devices will be considered ambulatory for the purpose of performance score determination
- For females of child-bearing age:
- Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
- Not lactating with intent to breastfeed
- Participants must be eligible to undergo autologous apheresis or have an available previously collected autologous apheresis product
- Treatment eligibility
- Age ≤ 21 years old at the time of manufacturing
- B7-H3+ sarcoma
- Evidence of relapsed or refractory disease after standard first-line therapy
- Evaluable disease with the presence of at least one lesion amenable to hypofractionated radiation therapy
- For dose expansion cohort: participants must also have additional evaluable disease beyond the planned radiation field
- Estimated life expectancy of > 8 weeks
- Karnofsky or Lansky (age-dependent) performance score ≥ 60
You may not qualify if…
- Collection and manufacturing eligibility
- Known primary immunodeficiency
- Known HIV positivity
- Severe, uncontrolled intercurrent bacterial, viral, or fungal infection
- Known active malignancy other than the B7-H3+ sarcoma being treated on study
- Rapidly progressive disease (as assessed by the study PIs, with consideration for proximity to critical structures)
- Presence of intracranial or spinal cord disease
- Known underlying medical condition(s) for which, in the investigator's opinion, participation in this trial would not be in the best interest of the participant (e.g., compromises the health of the subject) or that could prevent, limit, or confound protocol assessments
- Known severe hypersensitivity to corn starch or hydroxyethyl starch
- Treatment eligibility
- Known primary immunodeficiency
- Known HIV positivity
- Severe, uncontrolled intercurrent bacterial, viral, or fungal infection
- Known active malignancy other than the B7-H3+ sarcoma being treated on study
- Receiving systemic steroid therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, < 7 days prior to CAR T cell infusion
- Receiving systemic therapy < 14 days prior to start of protocol therapy, which will interfere with the activity of the CAR product (in the opinion of the study PIs)
- Received radiation therapy within the 4 weeks prior to start of protocol therapy
- Rapidly progressive disease (as assessed by the study PIs, with consideration for proximity to critical structures)
- Presence of intracranial or spinal cord disease
- Known underlying medical condition(s) for which, in the investigator's opinion, participation in this trial would not be in the best interest of the participant (e.g., compromises the health of the subject) or that could prevent, limit, or confound protocol assessments
- Known severe hypersensitivity to corn starch or hydroxyethyl starch
Where it is running
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.